Preventogen™ eradicated Candida auris antibiotic-resistant strain by 99.99% at 30, 90 and 120 seconds with a formidable 5.61 log reduction.

ST. LOUIS, MO / ACCESS Newswire / January 7, 2026 / Scientists have identified a new ally in the battle against the deadly outbreak of the superbug Candida auris, currently spreading rapidly throughout U.S. Hospitals and becoming even more threatening worldwide. An independent laboratory study shows that Preventogen, an FDA-cleared microbicidal liquid polymer, kills 99.99 percent of the C. auris fungus on contact. The triple-action liquid product, which eliminates drug-resistant bacteria, viruses and fungi, can now be used to prevent the spread of the superbug plaguing healthcare facilities across the world.

According to the Centers for Disease Control, C. auris presents a serious global health threat because the fungus is often multidrug-resistant, difficult to identify with standard lab tests, and has caused recent outbreaks in healthcare settings. Over 7,000 cases have been confirmed across dozens of U.S. states in 2025, and according to the CDC has been identified in over 60 countries. Further, more than one-third of patients who develop invasive C. auris infection die within a few months of exposure, making it imperative to identify a preventative agent.

Preventogen has answered that need. When applied to the skin, Preventogen kills all organisms - bacteria, viruses and fungi - on contact. As it dries, its patented polymer creates an elastomeric flexible film that seals over the wound, protecting against water, germs and dirt. The lowered pH of the sealed wound creates an environment that promotes wound healing. No other known cidal agent protects against superbugs while also protecting wounds and optimizing healing.

"This pathogenic fungus shows an innate resilience enabling survival and persistence in healthcare environments and the ability to rapidly colonize on the patient's skin and be easily transmitted within the healthcare setting", said Dr Samir S. Awad MD, MPH, Chief Medical Officer at Prevent-Plus. "We have extensively studied the use of Preventogen in the reduction of surgical site infections, pin-site infections and dialysis catheter infections. Preventogen may be an important tool to winning the battle in this world-wide outbreak by preventing C. auris from entering the tissue or bloodstreams of compromised patients."

Grady Wertman, Study Director/Supervisor of Laboratory Personnel at BioScience Laboratories, which performed the in-vitro testing of Preventogen's effect on C. auris says, "When testing for Preventogen's microbiocidal properties, when applied to C. auris, Preventogen eliminated 99.99 percent of the fungus within 30 seconds."

Preventogen, a non-antibiotic approach to infection prevention, is a 510(k) FDA-cleared Class I medical device indicating a high level of quality, safety and effectiveness. Importantly, because it is not a drug, there are no known organisms with tolerance of or resistance to it. Preventogen is made in the United States and is cleared for both hospital and over-the-counter use.

For more information, please visit Preventogen.com or email info@preventogen.com.

About Prevent-Plus and Preventogen:

Prevent-Plus is an ISO 13485-certified manufacturer of Preventogen, an FDA-cleared advanced infection prevention solution that uses liquid polymer technologies. Preventogen is Prevent-Plus's hospital-grade product designed for use in clinical settings. This advanced wound care solution provides a non-antibiotic approach to infection prevention and active healing, killing microbes (bacteria, fungi, and viruses) on contact before forming a flexible, breathable polymer barrier. Backed by scientific and clinical data, Preventogen is designed for use across a wide range of acute and chronic wound types.

Company Contact:
Prevent-Plus / Preventogen
Brad Chartrand, CEO
(518) 796-8786
bchartrand@preventogen.com

Media/PR Contact:
Prevent-Plus / Preventogen
Lena Geandreau, VP Marketing
(917) 848-0138
lgeandreau@preventogen.com

SOURCE: Prevent-Plus